According to the research report titled, ‘Pulmonary Arterial Hypertension Market Size By Drug Class, By Route of Administration (Oral, Intravenous, Inhalation), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027’, available with MarketStudyReport, global pulmonary arterial hypertension market is anticipated to amass notable gains during 2021-2027.
 

Rising prevalence of cardiovascular diseases and increasing geriatric population are boosting the growth of global pulmonary arterial hypertension industry.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4202298/
 

For the unversed, lifestyle habits like drinking, smoking, and excessive consumption of packaged foods are known as the major causes for pulmonary arterial hypertension (PAH). The world has seen a major surge in cardiovascular diseases post the COVID-19 pandemic outbreak. The viral infection has been found to be the cause behind the occurrence or escalation of such ailments in patients, especially in those who are above 65 years of age.
 

In addition, growing focus on creating effective therapies and drugs to treat PAH, backed by favorable government initiatives and policies for research & development is adding momentum to market progression. Citing an instance, in August 2021, the Food and Drug Administration (FDA) gave its approval to the Uptravi (selexipag) injection used for treating PAH in adult patients (PAH, WHO Group I).
 

On the contrary, the expansion of worldwide pulmonary arterial hypertension market is likely to be hampered by side effects associated with drugs used to treat the disease, along with the expiration of several drug patents.
 

By drug class, the vasodilators segment captured a significant market share in 2020 and was worth around USD 1,365 million, mainly driven by the capability of these products to increase the rate of survival among critical patients.
 

In terms of route of administration, intravenous segment is projected to accumulate a revenue of USD 1,555 million by the end of 2027, owing to fast-acting and effective form of drug delivery offered by intravenous therapy.
 

Considering the regional terrain, Middle East & Africa market was worth USD 124 million in 2020 and is slated to expand considerably during 2021-2027, creditable to rising cases of PAH disorder across the region.
 

Key players operating in global pulmonary arterial hypertension market sphere are United Therapeutics Corporation, Pfizer, Inc., Johnson & Johnson Services, Inc., Glaxo SmithKline plc, Gilead Sciences, Inc., Eli Lilly and Company, and Bayer AG.